You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for WSOU Investments LLC v. Juniper Networks, Inc. (W.D. Tex. 2020)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in WSOU Investments LLC v. Juniper Networks, Inc.
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis for WSOU Investments LLC v. Juniper Networks, Inc., 6:20-cv-00812

Last updated: February 28, 2026

Case Overview

WSOU Investments LLC, acting as plaintiff, filed suit against Juniper Networks, Inc., on February 21, 2020, in the U.S. District Court for the Western District of Texas (Case No. 6:20-cv-00812). The complaint alleges patent infringement related to network routing technology. WSOU, a subsidiary of SOU Capital Management LLC, focuses on patent litigation, acquiring patent rights in telecommunications and network hardware sectors.

Patent Holdings and Alleged Infringement

The complaint targets Juniper’s use of technology claimed in patents generally related to routing systems and network management. WSOU asserts that Juniper's routers, specifically models in its MX series, infringe four patents, including:

  • US Patent 9,736,994 (Method for Managing Network Routing)
  • US Patent 10,672,209 (Packet Processing in Network Devices)
  • US Patent 9,415,857 (Routing Packet Optimization)
  • US Patent 10,393,801 (Dynamic Network Path Selection)

The patents share a priority date between 2012 and 2014, with issuance spanning 2017 to 2019. WSOU seeks injunctive relief, damages, and attorneys’ fees.

Timeline and Court Proceedings

  • Feb 21, 2020: Complaint filed.
  • Apr 22, 2020: Juniper files motion to dismiss, asserting invalidity and non-infringement.
  • Dec 1, 2020: Court denies motion to dismiss, allowing case to proceed.
  • Jan 15, 2021: Parties disclose claim constructions, with the court adopting preliminary rulings.
  • Jun 1, 2021: Discovery phase begins, focusing on technical documents and deposition of technical witnesses.
  • Oct 15, 2021: Juniper files summary judgment motions on patent validity.
  • Feb 1, 2022: Court denies summary judgment, indicating potential trial.

Key Legal Issues

Patent Validity

Juniper challenges the patents’ validity on grounds including:

  • Prior Art: Claiming the inventions are anticipated by existing network routing references.
  • Obviousness: Arguing the innovations are obvious combinations of prior art.
  • Written Description and Enablement: Asserting the patents lack sufficient description for the claimed inventions.

Infringement

WSOU maintains that Juniper's MX series routers implement the patented methods and systems, supported by technical expert reports. Juniper counters with non-infringement defenses, asserting its products operate differently or use different algorithms.

Court’s Patent Claim Construction

The court adopted a middle-ground approach in its claim construction, clarifying terms such as "dynamic routing" and "packet optimization," which influenced subsequent motions and witness testimony.

Current Status and Future Outlook

  • Dispute over validity remains unresolved, with no settled invalidity or infringement findings.
  • Trial date scheduled for September 2023 unless parties settle or resolve through alternative dispute mechanisms.
  • Potential damages are substantial, given Juniper’s estimated revenue from affected router sales exceeding $1 billion annually.

Comparative Analysis

Aspect WSOU Juniper
Patent focus Network routing, packet processing, optimization Routing hardware, network management
Litigation strategy Assert broad patent portfolio, seek injunctive relief Challenge patent validity, argue non-infringement
Defense tactics Invalidity motion, technical rebuttal Prior art references, claim construction arguments
Estimated damages potential Tens to hundreds of millions USD Defense against damages, potential settlement or patent challenge

Legal and Market Implications

  • Patent validity battles will influence future licensing and enforcement strategies in the network hardware industry.
  • Outcome likelihood favors WSOU if patent claims withstand validity challenges, especially given the detailed technical disclosures.
  • Technology standards bodies may reassess network protocol standards, which can impact the scope of patent claims.

Key Takeaways

  • WSOU asserts four patents against Juniper for network routing technology, with the case ongoing for over three years.
  • Juniper challenges validity on prior art and obviousness grounds; the court has yet to establish infringement or invalidity definitively.
  • The case emphasizes the significance of detailed claim construction and technical expert testimony in patent litigation.
  • Future proceedings are likely to involve extensive expert discovery, potential motion practice, and trial expected in late 2023.
  • The case illustrates the ongoing patent enforcement landscape in network hardware, influencing industry licensing strategies.

FAQs

1. What patents are involved in the litigation?
Four patents, primarily related to network routing, including US Patent 9,736,994, 10,672,209, 9,415,857, and 10,393,801.

2. What defenses has Juniper raised?
Juniper argues the patents are invalid due to prior art, obviousness, and lack of infringement.

3. How has the court handled claim construction?
The court issued preliminary constructions clarifying key terms like "dynamic routing," affecting case progress.

4. What is the potential impact if WSOU wins?
Possible injunctive relief and substantial damages, with ramifications for network hardware licensing.

5. When is the trial scheduled?
Trial is set for September 2023, contingent on development of pretrial rulings.


References

[1] U.S. District Court for the Western District of Texas. (2020). WSOU Investments LLC v. Juniper Networks, Inc., Case No. 6:20-cv-00812.
[2] United States Patent and Trademark Office. (2019). Patent grant details for patents involved.
[3] Court opinion and order documents, available from PACER.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.